Vilazodone Hydrochloride

A benzofuran, indole, and piperazine derivative that functions as a SEROTONIN UPTAKE INHIBITOR and partial SEROTONIN 5-HT1 RECEPTOR AGONIST. It is used as an ANTIDEPRESSIVE AGENT.

Also Known As:

2-benzofurancarboxamide, 5-(4-(4-(5-cyano-1H-indol-3-yl)butyl)-1-piperazinyl)-, hydrochloride (1:1); 5-(4-(4-(5-cyano-3-indolyl)butyl)-1-piperazinyl)benzofuran-2-carboxamide; EMB-68843; EMD 68843; Viibryd; Vilazodone; Vilazodone HCl; 68843, EMD; EMB 68843; EMB68843; HCl, Vilazodone; Hydrochloride, Vilazodone

Networked: 126 relevant articles (17 outcomes, 42 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - Vilazodone Hydrochloride: 126
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Vilazodone Hydrochloride: 126
    - Benzofurans: 26
      - Vilazodone Hydrochloride: 126

Experts

1.	Edwards, John: 11 articles (08/2018 - 03/2013)
2.	Mathews, Maju: 11 articles (01/2017 - 01/2014)
3.	Durgam, Suresh: 9 articles (11/2018 - 06/2015)
4.	Gommoll, Carl: 8 articles (11/2018 - 11/2014)
5.	Nunez, Rene: 7 articles (12/2016 - 11/2014)
6.	Thase, Michael E: 6 articles (11/2018 - 01/2012)
7.	Tang, Xiongwen: 6 articles (12/2016 - 03/2015)
8.	Gallipoli, Susan: 6 articles (10/2013 - 04/2011)
9.	Reed, Carol R: 6 articles (10/2013 - 03/2009)
10.	Chen, Changzheng: 5 articles (11/2018 - 01/2016)

Related Diseases

1.	Major Depressive Disorder (Major Depressive Disorders) 01/01/2016 - "In three 8-week studies of vilazodone 40 mg/d (NCT00285376, NCT00683592, and NCT01473394) and a 10-week study of vilazodone 20 or 40 mg/d (NCT01473381), adults with major depressive disorder (MDD) showed significantly greater improvement with vilazodone versus placebo in global disease severity as measured by mean change from baseline in Clinical Global Impression of Severity (CGI-S) score. " 02/01/2014 - "Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials." 11/01/2014 - "Vilazodone may be effective in treating patients with major depressive disorder who exhibit somatic and/or psychic symptoms of anxiety. " 01/01/2014 - "To assess clinically relevant symptom improvement in patients with major depressive disorder (MDD) receiving vilazodone by using the Montgomery-Asberg Depression Rating Scale (MADRS), a clinician-rated scale used to measure MDD symptom severity and improvement. " 07/01/2011 - "Vilazodone: a new treatment option for major depressive disorder."
2.	Anxiety Disorders (Anxiety Disorder) 04/01/2017 - "Vilazodone is an effective treatment for generalized anxiety disorder, though further trials are required for a more adequate comparison with established treatments, as well as long term maintenance studies to determine the validity of claims regarding the absence of sexual side effects." 04/01/2017 - "A systematic review and meta-analysis of all relevant randomized controlled trials was conducted to evaluate the safety and efficacy of vilazodone in the acute treatment of generalized anxiety disorder (GAD). " 12/01/2016 - "Efficacy and Safety of Vilazodone in Patients With Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Trial." 01/01/2016 - "Vilazodone has been shown to reduce core symptoms of generalized anxiety disorder (GAD) in three randomized, double-blind, placebo-controlled trials. " 01/01/2016 - "Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies."
3.	Fatigue 01/01/2014 - "A significantly greater proportion of vilazodone-treated versus placebo-treated patients shifted from baseline ≥ 4 to end of study ≤ 2 on MADRS items of apparent sadness, reported sadness, inner tension, reduced sleep, and lassitude (OR range, 1.5-2.0, P < .05). " 06/01/2015 - "Nausea, diarrhea, dizziness, vomiting, and fatigue were reported in ≥5% of patients in either vilazodone group and at least twice the rate of placebo. " 12/01/2016 - "Treatment-emergent adverse events reported in ≥ 5% of vilazodone patients and at least twice the rate of placebo were nausea, diarrhea, dizziness, fatigue, delayed ejaculation, and erectile dysfunction. "
4.	Marijuana Abuse (Cannabis Abuse) 01/01/2016 - "Vilazodone for cannabis dependence: A randomized, controlled pilot trial." 01/01/2016 - "The purpose of this study was to evaluate the efficacy of vilazodone, a selective serotonin receptor inhibitor and partial 5-HT1A agonist, for treatment of cannabis dependence. "
5.	Social Phobia 01/01/2015 - "The findings suggest that vilazodone may be a promising treatment for social anxiety disorder. " 01/01/2015 - "Forty-four subjects with generalized social anxiety disorder (DSM-IV-TR criteria) were randomized to vilazodone or placebo in a 12-week double-blind, flexible-dose trial. " 01/01/2015 - "A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Vilazodone in Generalized Social Anxiety Disorder." 01/01/2015 - "To examine the efficacy, safety, and tolerability of vilazodone for subjects (aged 18-75 years) with generalized social anxiety disorder. "

Related Drugs and Biologics

1.	Antidepressive Agents (Antidepressants)
2.	Escitalopram
3.	Vortioxetine
4.	Levomilnacipran
5.	Sertraline (Zoloft)
6.	Serotonin 5-HT1 Receptor Agonists
7.	Serotonin Receptors
8.	Venlafaxine Hydrochloride (Effexor)
9.	Paroxetine (Paxil)
10.	Duloxetine Hydrochloride (Cymbalta)

Related Therapies and Procedures

1.	Secondary Prevention
2.	Injections
3.	Therapeutics
4.	Induced Hyperthermia (Thermotherapy)
5.	Drug Therapy (Chemotherapy)